2. Others Autophagy Anti-infection
  3. Parasite HSV Autophagy Dengue Virus Flavivirus HIV Environmental Pollutants Mitophagy Bacterial Antibiotic SARS-CoV
  4. Ivermectin

Ivermectin  (Synonyms: MK-933; CD-5024; K-237)

Cat. No.: HY-15310 Purity: 98.28%
COA
SDS
Handling Instructions Technical Support

Ivermectin (MK-933) is a broad-spectrum anti-parasite agent. Ivermectin (MK-933) is a specific inhibitor of Impα/β1-mediated nuclear import and has potent antiviral activity towards both HIV-1 and dengue virus. It is a positive allosteric effector of P2X4 and the α7 neuronal nicotinic acetylcholine receptor (nAChRs). Ivermectin also inhibits bovine herpesvirus1 (BoHV-1) replication and inhibits BoHV-1 DNA polymerase nuclear import. Ivermectin is a candidate therapeutic against SARS-CoV-2/COVID-19.

For research use only. We do not sell to patients.

CAS No. : 70288-86-7

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
500 mg In-stock
1 g In-stock
5 g In-stock
10 g   Get quote  
50 g   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 48 publication(s) in Google Scholar

Ivermectin Related Antibodies

Top Publications Citing Use of Products

48 Publications Citing Use of MCE Ivermectin

In Vivo Efficacy Study
WB
Flow Cytometry
Cell Autophagy Assay

    Ivermectin purchased from MedChemExpress. Usage Cited in: Sci Adv. 2025 Aug 15;11(33):eadx6587.  [Abstract]

    Ivermectin (IVM; 12.5 mg/kg; ip). Tumor growth of B16 in C57BL/6 mice treated with IVM, α-PD-1, or both.

    Ivermectin purchased from MedChemExpress. Usage Cited in: Cell Mol Immunol. 2022 Aug;19(8):898-912.  [Abstract]

    Ivermectin (1-3 mg/kg; i.p.). Platelet counts in WT (upper panel) and Adap−/− mice (lower panel) treated with Ivermectin or saline over a time course of 5 days.

    Ivermectin purchased from MedChemExpress. Usage Cited in: Cell Mol Immunol. 2022 Aug;19(8):898-912.  [Abstract]

    Ivermectin (1-3 mg/kg; i.p.). FcγR expressions on resting and IFN-γ-treated splenic macrophages in WT and Adap−/− mice treated with ivermectin for 5 days from.

    Ivermectin purchased from MedChemExpress. Usage Cited in: Autophagy. 2022 Mar;18(3):559-575.  [Abstract]

    Ivermectin (IVE; 10 μM; 24 h). Hs-SNCA, p-SNCA, LC3-II and SQSTM1/p62 levels were elevated by western blotting.

    Ivermectin purchased from MedChemExpress. Usage Cited in: Autophagy. 2022 Mar;18(3):559-575.  [Abstract]

    Ivermectin (IVE; 10 μM; 24 h). Autophagy flux was evaluated by counting autophagosome (RFP-GFP double positive puncta) and autolysosomes (RFP-single positive puncta) in mRFP-GFP-LC3 primary neurons.

    View All Parasite Isoform Specific Products:

    View All Isoforms
    Amebae Coccidia Leishmania Mite Plasmodium Toxoplasma Trypanosoma Schistosome

    View All HSV Isoform Specific Products:

    View All Isoforms
    HSV-1 HSV-2 HSV

    View All HIV Isoform Specific Products:

    View All Isoforms
    HIV HIV-1 HIV-2

    View All Antibiotic Isoform Specific Products:

    View All Isoforms
    Aminoglycoside Glycopeptide Lipopeptide Macrolide Oxazolidinone Quinolone Tetracycline β-lactam

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Ivermectin (MK-933) is a broad-spectrum anti-parasite agent. Ivermectin (MK-933) is a specific inhibitor of Impα/β1-mediated nuclear import and has potent antiviral activity towards both HIV-1 and dengue virus. It is a positive allosteric effector of P2X4 and the α7 neuronal nicotinic acetylcholine receptor (nAChRs). Ivermectin also inhibits bovine herpesvirus1 (BoHV-1) replication and inhibits BoHV-1 DNA polymerase nuclear import[1][2][3][4]. Ivermectin is a candidate therapeutic against SARS-CoV-2/COVID-19[5].

    IC50 & Target[1]

    HIV-1

     

    DNA Polymerase

     

    HSV-1

     

    BoHV-1

     

    SARS-CoV-2

     

    In Vitro

    In the submicromolar range (EC50=250 nM) the action of Ivermectin (MK-933) is rapid and reversible, resulting in increased amplitude and slowed deactivation of P2X4 channel currents evoked by ATP[1].
    Ivermectin (MK-933) markedly increases the potency of ATP and that of the normally low-potency agonist a,b-methylene-ATP in a use- and voltage-independent manner without changing the ion selectivity of P2X4 channels[1].
    Ivermectin (MK-933) activates glutamate-gated chloride channels in the nerves and muscles of the parasite, leading to membrane hyperpolarization and muscle paralysis[2].
    Ivermectin (MK-933) strongly inhibits the binding of Impα/β1 to NS5 (IC50=17 μM), but not of Impβ1 alone to NS5[3].
    Ivermectin (MK-933) has potent antiviral activity towards both HIV-1 and dengue virus, both of which are strongly reliant on importin α/β nuclear import, with respect to the HIV-1 integrase and NS5 (non-structural protein 5) polymerase proteins respectively[3].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Ivermectin Related Antibodies
    Clinical Trial
    Molecular Weight

    875.09

    Formula

    C48H74O14
    CAS No.
    Appearance

    Solid

    Color

    White to off-white

    SMILES

    CO[C@H]1C[C@H](O[C@H]2[C@H](C)O[C@@H](O[C@H](/C(C)=C/C[C@@H]3C[C@H]4C[C@@]5(O[C@]([H])(C(C)C)[C@@H](C)CC5)O3)[C@@H](C)/C=C/C=C6CO[C@@]7([H])[C@]\6(O)[C@H](C(O4)=O)C=C(C)[C@H]7O)C[C@@H]2OC)O[C@@H](C)[C@@H]1O.CO[C@H]8C[C@H](O[C@H]9[C@H](C)O[C@@H](O[C@H](/C(C)=C/C[C@@H]%10C[C@H]%11C[C@@]%12(O[C@]([H])([C@@H](C)CC)[C@@H](C)CC%12)O%10)[C@@H](C)/C=C/C=C%13CO[C@@]%14([H])[C@]\%13(O)[C@H](C(O%11)=O)C=C(C)[C@H]%14O)C[C@@H]9OC)O[C@@H](C)[C@@H]8O
    Structure Classification
    Initial Source

    Streptomyces avermitilis
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 2 years
    -20°C 1 year
    Solvent & Solubility
    In Vitro: 

    DMSO : 250 mg/mL (285.68 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    H2O : < 0.1 mg/mL (insoluble)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 1.1427 mL 5.7137 mL 11.4274 mL
    5 mM 0.2285 mL 1.1427 mL 2.2855 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.5 mg/mL (2.86 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% Corn Oil

      Solubility: ≥ 2.08 mg/mL (2.38 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

    For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  50% PEG300    50% Saline

      Solubility: 3.33 mg/mL (3.81 mM); Suspended solution; Need ultrasonic

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    Purity & Documentation

    Purity: 98.28%

    SDS (623 KB)

    COA (266 KB) HNMR (413 KB) LCMS (97 KB)

    Handling Instructions (2659 KB)
    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 1.1427 mL 5.7137 mL 11.4274 mL 28.5685 mL
    5 mM 0.2285 mL 1.1427 mL 2.2855 mL 5.7137 mL
    10 mM 0.1143 mL 0.5714 mL 1.1427 mL 2.8568 mL
    15 mM 0.0762 mL 0.3809 mL 0.7618 mL 1.9046 mL
    20 mM 0.0571 mL 0.2857 mL 0.5714 mL 1.4284 mL
    25 mM 0.0457 mL 0.2285 mL 0.4571 mL 1.1427 mL
    30 mM 0.0381 mL 0.1905 mL 0.3809 mL 0.9523 mL
    40 mM 0.0286 mL 0.1428 mL 0.2857 mL 0.7142 mL
    50 mM 0.0229 mL 0.1143 mL 0.2285 mL 0.5714 mL
    60 mM 0.0190 mL 0.0952 mL 0.1905 mL 0.4761 mL
    80 mM 0.0143 mL 0.0714 mL 0.1428 mL 0.3571 mL
    100 mM 0.0114 mL 0.0571 mL 0.1143 mL 0.2857 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Ivermectin Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Ivermectin70288-86-7MK-933 CD-5024 K-237MK933MK 933CD5024CD 5024CD-5024K237K 237K-237ParasiteHSVAutophagyDengue VirusFlavivirusHIVEnvironmental PollutantsMitophagyBacterialAntibioticSARS-CoVHerpes simplex virusDENVHuman immunodeficiency virusEnvironmental ContaminantsMitochondrial AutophagySARS coronavirusInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Requested Quantity *

    Applicant Name *

    		 

    Salutation

    Email Address *

    		 

    Phone Number *

    Department

    		 

    Organization Name *

    City

    State

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Ivermectin
    Cat. No.:
    HY-15310
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    SAFETY DATA SHEET (SDS)

    English - EN (623 KB) Français - FR (623 KB) Deutsch - DE (623 KB) Norwegian - NO (623 KB) Español - ES (623 KB) Swedish - SV (623 KB) Italian - IT (623 KB) Korean - KR (623 KB) Portuguese - PT (623 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.